On the probability of cost-effectiveness using data from randomized clinical trials

BMC Medical Research Methodology

Volumn 1, Issue , 2001, Pages 1-5

  Willan, Andrew R ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANALYTIC METHOD; ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DATA ANALYSIS; HEALTH CARE COST; HUMAN; HYPOTHESIS; PARAMETER; PATIENT; PROBABILITY; QUANTITATIVE ANALYSIS; RANDOMIZATION; SAMPLE SIZE;

EID: 3042833395     PISSN: 14712288     EISSN: None     Source Type: Journal    
DOI: 10.1186/1471-2288-1-8     Document Type: Article

References (14)

1. van Hout BA, Al MJ, Gordon GS, Rutten EFH: Cost, effects and C/E-ratios alongside a clinical trial. Health Economics 1994, 3:309-319
2. Brigg A, Fenn P: Confidence intervals or surfaces? Uncertainty on the cost-effectiveness plane. Health Economics 1998, 7:723-740
3. Briggs AH: A Bayesian approach to stochastic cost-effectiveness analysis. Health Economics 1999, 8:257-261
4. Raikou M, Gray, Briggs, Stevens A, Cull C, McGuire A, Fenn P, Stratton I, Holman R, Turner R: Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes: UKPDS 40. British Medical Journal 1998, 317:720-726
5. Phelps CE, Mushlin AI: On the (near) equivalence of cost-effectiveness and cost-benefit analysis. International Journal of Technology Assessment in Health Care 1991, 7:12-21
6. Ament A, Baltussen R: The interpretation of results of economic evaluation: explicating the value of health. Health Economics 1997, 6:625-635
7. Stinnett AA, Mallahy J: Net health benefits: a new framework for the analysis of uncertainty in cost-effectiveness analsyis. Medical Decision Making 1998, 18 Suppl.:S68-S80
8. Tambour M, Zethraeus, Johannesson M: A note on confidence intervals in cost-effectiveness analysis. International Journal of Technology Assessment 1998, 14:467-471
9. Willan AR, Lin DY: Incremental net benefit in randomized clinical trials. Statistics in Medicine 2001, 20:1563-1574
10. DeLong ER, DeLong DM, Clake-Pearson DL: Comparing the area under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988, 44:837-845
11. Tannock IF, Osoba D, Stockler MR, Ernst DS, Neville AJ, Moore MJ, Armitage GR, Wilson JJ, Venner PM, Coppin CM, Murphy KC: Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian trial with palliative endpoints. Journal of Clinical Oncology 1996, 14:1756-1764
12. Bloomfield DJ, Krahn MD, Neogi T, Panzarella T, Warde P, Willan AR, Ernst S, Moore MJ, Neville A, Tannock IF: Economic evaluation of chemotherapy with mitoxantrone plus prednisone for symptomatic hormone-resistant prostate cancer: based on a Canadian trial with palliative endpoints. Journal of Clinical Oncology 1998, 16:2272-2279
13. Willan AR, O'Brien BJ: Confidence intervals for cost-effectiveness ratios: An application of Fieller's theorem. Health Economics 1996, 5:297-305
14. Chaudhary MA, Stearns SC: Confidence intervals for cost-effectiveness ratios: an example from a randomized trial. Statistics in Medicine 1996, 15:1447-1458